Description

Anti-inflammatory drugs block certain substances in the body that cause inflammation ((redness, swelling, and pain)). They are used to treat many different conditions. The global anti-inflammatory drugs market is set to increase by US$ 43.8 billion from 2022 to 2028, representing a compound annual growth rate (CAGR) of 6.1% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for anti-inflammatory drugs. The global anti-inflammatory drugs market is segmented on the basis of drug class, indication, route of administration, and region. On the basis of drug class, the global anti-inflammatory drugs market has been segmented into biologics & biosimilars, non-steroidal anti-inflammatory drugs (NSAIDs), steroids, others. The biologics & biosimilars segment held the largest revenue share in 2021. By indication, the global anti-inflammatory drugs market has been segmented into autoimmune diseases, respiratory diseases, others. Among these, the autoimmune diseases segment was accounted for the highest revenue generator in 2021. Based on route of administration, the global anti-inflammatory drugs market is categorized into parenteral, oral, topical, inhalational. In terms of geography, the global anti-inflammatory drugs market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). According to the research, North America had the largest share in the global anti-inflammatory drugs market.

The global anti-inflammatory drugs market is highly competitive. Some of the leading companies operating in the market are AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Glenmark Pharmaceuticals Limited, GSK plc, Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi S.A.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the anti-inflammatory drugs market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Drug class: biologics & biosimilars, non-steroidal anti-inflammatory drugs (NSAIDs), steroids, others
Indication: autoimmune diseases, respiratory diseases, others
Route of administration: parenteral, oral, topical, inhalational
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global anti-inflammatory drugs market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Anti-inflammatory drugs market overview
Part 3. Market breakdown by drug class
– Biologics & biosimilars
– Non-steroidal anti-inflammatory drugs (NSAIDs)
– Steroids
– Others
Part 4. Market breakdown by indication
– Autoimmune diseases
– Respiratory diseases
– Others
Part 5. Market breakdown by route of administration
– Parenteral
– Oral
– Topical
– Inhalational
Part 6. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 7. Key companies
– AbbVie Inc.
– Amgen Inc.
– AstraZeneca plc
– Bayer AG
– Biogen Inc.
– Bristol-Myers Squibb Company
– Cipla Limited
– Dr. Reddys Laboratories Ltd.
– Eli Lilly and Company
– F. Hoffmann-La Roche AG
– Glenmark Pharmaceuticals Limited
– GSK plc
– Johnson & Johnson
– Merck & Co., Inc.
– Novartis International AG
– Pfizer Inc.
– Sanofi S.A.
About StrategyHelix
Disclaimer